CJC 1295 (without DAC) CND5 5mg*10vials

CJC 1295 (DAC-free) CND5 5mg*10 vials is an upgraded intermediate-acting, short-acting physiological growth hormone-releasing hormone (GHRH) analog research peptide, a mid-range upgrade from the basic CND2. CND5 retains the original peptide structure without DAC modification and albumin-binding modification, thus maintaining its natural rapid metabolic clearance and standard short half-life pulsatile growth hormone release characteristics. CND5 optimizes molecular activity and uses a standard intermediate concentration of 5mg. Compared to low-dose CND2, it significantly enhances the pulsatile activation efficiency of the GH/IGF-1 axis and produces a more significant physiological phenotype, thus achieving a balance between pure physiological pulsatile mimicry and efficient metabolic regulation. CND5 is ideal for intermediate-dose gradient efficacy studies, moderate-intensity acute anabolic interventions, pulsatile body composition remodeling, and validation of synergistic peptide combination mechanisms. As a core mainstream upgrade product in the short-acting GHRH peptide class, CJC 1295 CND5 covers most mid-stage preclinical endocrinology and metabolic research scenarios.

Product Functions and Research Value

In systematic laboratory studies, CJC 1295 CND5, without DAC, triggered strong, orderly, physiologically pulsatile GH secretion and moderate IGF-1 elevation, perfectly mimicking the body's natural intermittent endocrine rhythms. Due to the absence of DAC albumin retention, excess peptides are rapidly metabolized and cleared, completely avoiding hormone accumulation and continuous overstimulation. Compared to mild, low-dose CND2, CND5 exhibits more comprehensive enhanced acute anabolism efficiency, faster fat metabolism activation, and more pronounced short-cycle tissue repair effects, resulting in intuitive and distinguishable experimental results. Its core research value lies in exploring the mechanisms of moderate-intensity pulsatile lean muscle synthesis, efficient acute fat breakdown and remodeling, moderate tissue damage repair, and moderate threshold endocrine dose response. CND5 possesses purely physiological pulse regulation characteristics, requires no endocrine desensitization, and suffers from minimal experimental interference. It is an ideal choice for intermediate-dose gradient experiments, synergistic validation with growth hormone secretagogues, and mid-term acute metabolic intervention modeling. It provides highly discriminative and reproducible physiological data for in-depth research into the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis mechanism.

Core Product Advantages

1. CND5 Intermediate Enhanced Iterative Version: An upgraded version based on CND2, optimizing molecular target activity and binding efficiency. It retains 100% authentic non-DAC physiological pulse characteristics while significantly enhancing endocrine activation intensity, bridging the gap between low-dose baseline studies and high-dose ultra-short-acting studies.

2. Standard Short Half-Life Physiological Pulse: Utilizing pure, unmodified, unprocessed peptide chains, ensuring natural and rapid metabolic clearance. It achieves pure, intermittent growth hormone pulse output without hormone superposition or accumulation, perfectly replicating the true physiological rhythms of the human endocrine system. 3. 5mg Balanced Medium-Acting Strength: A classic mainstream medium-concentration formulation in the CND series, addressing the issue of insufficient phenotypic differentiation in low-dose CND2 products. Balancing experimental safety and efficacy, it is the preferred strength for most routine medium-gradient studies and complex peptide synergistic studies.

4. High Purity and Low-Interference Regulation: Highly specific and precise targeting of the GHRH-GH-IGF-1 core pathway. Stable inducing physiological pulsatile secretion without interfering with stress hormones such as cortisol and prolactin, ensuring the purity of experimental variables and reliable mechanistic conclusions.

5. Pharmaceutical-Grade Quality and Standard Packaging: Aseptic vacuum freeze-drying process completely locks in the peptide's inherent activity. Each batch undergoes rigorous HPLC purity testing and comes with a complete official Certificate of Account (COA). Aseptically packaged in 10-vial packs, suitable for medium-sized laboratory research, key endocrinology projects in universities, and bulk wholesale purchases.

CJC 1295 (excluding DAC) CND5 5mg*10 vials is a medium-potency, late-stage research peptide, a short-acting physiological growth hormone-releasing hormone (GHRH) analogue, and the mid-term flagship product of the CND series. This is a comprehensive upgrade and enhancement of the basic version, CND2. This product retains the pure, DAC-free natural peptide chain structure and albumin-binding modification, thus maintaining its core physiological characteristics of natural rapid metabolic clearance and standard short-acting pulsed release. Through molecular activity optimization and upgrades, it incorporates…